NovoCure (NVCR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual ...

Key Takeaways Four GARP stocks, FLEX, CVS, URBN, and EXEL, were selected using a screen focused on PEG and value scores. Each pick has a PEG ratio below industry median, solid earnings outlook and a Zacks Rank of #1 or #2. FLEX leads with a 35.1% historical growth rate, while EXEL boasts 21.2% expected long-term earnings growth.In the equity market, investments always need to be prudently hedged to overcome uncertainties and limit losses related to external shocks. A question that often arises is whether ...